Filing Details
- Accession Number:
- 0001209191-21-046303
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-07-12 17:07:29
- Reporting Period:
- 2021-07-08
- Accepted Time:
- 2021-07-12 17:07:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1527753 | Personalis Inc. | PSNL | Services-Medical Laboratories (8071) | 275411038 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1779811 | Stephen John West | C/O Personalis, Inc. 1330 O'Brien Drive Menlo Park CA 94025 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-07-08 | 110,000 | $0.44 | 745,520 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2021-07-08 | 110,000 | $22.54 | 635,520 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-07-08 | 110,000 | $0.00 | 110,000 | $0.44 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 267,499 | 2022-03-07 | No | 4 | M | Direct |
Footnotes
- The weighted average sale price for the transaction reported was $22.54, and the range of prices were between $21.37 and 22.85. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The Shares subject to the option are fully vested and exercisable.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Billionaire Hedge Funds
